Kalofonos Isabel's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Jan 7, 2026
- Accession no.
- 0001628280-26-001230
- Filed
- Jan 7, 2026
- Trade date
- Jan 5, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $137.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kalofonos IsabelCIK 0001975163 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Common Stock | MOption exerciseAcquired | +2,500 | $40.59 | +$101,475 | 3,334 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −2,500 | $55.00F3 | −$137,500 | 834 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Common Stock | MOption exerciseDisposed | −2,500 | $0.00 | $0 | 97,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The common stock was sold by the Reporting Person in an open market transaction on the transaction date, at a sale price of $55.00 per share.
Referenced by the price of 1 transaction in Table I.